Introduction
Glaucoma refers to a collection of diseases whereby increased intraocular
pressureadversely impacts the optic nerve, and subsequently, the visual field. 1
Normal Tension Glaucoma-Normal IOP (10-21mmHg)
Have in common a characteristic progressive optic neuropathy
Eventual development of distinctive irreversible structural and functional visual
dysfunction
Epidemiology
Third leading cause of blindness (<3/60)
Fourth leading cause of all vision loss worldwide
Leading cause of irreversible vision loss. 3
Global prevalence 2.2-3.54% (40-80yrs). 4,5
19.4 percent ofblindness (<3/60) in Ghana. 6
76 million -2020.
122 million –2040. 5
2381 new cases of glaucoma out of 19445 OPD attendance at the eye clinic -
12.24%.
Two main class
1.Open –Angle Glaucoma
2.Close –Angle Glaucoma
It can be
Primary
Secondary
Common –Primary Open Angle Glaucoma (POAG)
Pathophysiology
Pathophysiology
Mechanical theory
elevated IOP leads to the compression of the nerve fibrebundle
Ischemic / Vascular theory
Hemodynamic alterations may act independently from, or in conjunction with,
raised IOP to cause damage at the site of the ONH
Glaucoma continuum
Symptoms
POAG is asymptomatic in its early stage
Visual field loss starts from the periphery to central
Can lead to complete loss of vision
Risk Factors
High Intraocular Pressure (>21mmHg)*
Ethnicity –Africans (4.2%), Europeans (2.1%), Asian (1.4%)7
Increasing age (>40yrs).
Positive family Hxof glaucoma
Refractive Status-high myopia
Central corneal thickness
Diabetes and Hypertension –weak association
Diagnosis-workup
Funduscopy
Gonioscopy*
Tonometry
Optical coherence tomography (OCT)
Visual field Test (VFT)
Pachymetry*
Management
Medication
Beta blockers –reduce production
Alpha agonist -reduce production
Carbonic Anhydrous Inhibitors -reduce production
Cholinergic Agonist –increase drainage
Prostaglandin analogues –increase drainage
Surgery
-Trabeculectomy
-SIGS/ MIGS
-Glaucoma Implant Surgery
Laser
-Trabeculoplasty
-Iridotomy
CONCLUSION
The statistic are not good
Enormous Global financial burden-Global cost of productivity losses
$244 billion –uncorrected myopia
$25.4 billion –presbyopia
(WHO FACTS SHEET)
1.NavidMahabadi; Lisa A. Foris; KoushikTripathy. Open Angle Glaucoma,
StatPearlsPublishing; 2022 Jan
2.CassonR, ChidlowG, Wood J, CrowstonJ, Goldberg I (2012) Definition of
glaucoma: clinical and experimental concepts. ClinExpOphthalmol40:341–
349. doi:10.1111/j.1442-9071.2012.02773.x
3.WHO, fact sheets, blindness and vision impairment 14 Oct 2021
4.Genetics of glaucoma. WiggsJL, Pasquale LR.Hum MolGenet.2017;26:0.
5.Yih-Chung Tham,Xiang Li,Tien Y Wong,Harry A Quigley,Tin Aung,Ching-Yu
Cheng, Global prevalence of glaucoma and projections of glaucoma burden
through 2040 a systemic review and meta-analysis. Ophthalmology 2014; 121:
2081-2090
6.Ghana Blindness and Visual Impairment Study 2015; 25
7.Leske, M.C Open-Angle Glaucoma-An epidemiologic overview, ophthalmic
epid, 2007 14(4); p 166-172